Taiwan Advance Bio-Pharmaceutical Inc. (TPEX:4186)

TPEX:4186 Revenue

Taiwan Advance Bio-Pharmaceutical had revenue of 153.10M TWD in the half year ending June 30, 2026, with 0.95% growth. This brings the company's total for the last twelve months to 348.54M, down -6.27% year-over-year. In the year 2025, Taiwan Advance Bio-Pharmaceutical had annual revenue of 364.79M with 3.00% growth. That makes Taiwan Advance Bio-Pharmaceutical the 37,049th largest company in the world by revenue and 1,941st in Taiwan.

• Revenue (ttm): 348.54M
• Revenue Growth: -6.27%
• P/S Ratio: 1.93
• Revenue / Employee: 2.18M
• Employees: 160
• Market Cap: 672.30M

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• Precise Medical Division 143.55M 39.4%
• Inspection Business Division 94.92M 26.0%
• New Business Division 88.68M 24.3%
• Food Safety Business Division 37.64M 10.3%

Fiscal year ended Dec 31, 2025 See the full TPEX:4186 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	364.79M	10.62M	3.00%
Dec 31, 2024	354.17M	38.19M	12.09%
Dec 31, 2023	315.98M	-2.25M	-0.71%
Dec 31, 2022	318.24M	74.87M	30.77%
Dec 31, 2021	243.36M	7.79M	3.31%

Data Source: S&P Global Market Intelligence Last updated: Aug 13, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 29, 2026

Data Sources Report a data error